HB Wealth Management 13F: Adds $8.3M to Eli Lilly and (LLY) Stake

In a Form 13F filing filed with the SEC on October 23, 2026, HB Wealth Management disclosed it boosted its stake in Eli Lilly and Company LLY by 11.1%. Form 13F reports give investors a quarterly look at what major investment managers are buying and selling. Eli Lilly shares closed at $1,273.46 on the day of the filing.

LLY Eli Lilly and Company

$1,273.46 ▲ +18.44% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in HB Wealth Management's Eli Lilly Position

The firm added 7,180 shares during the period, growing its investment to 71,632 shares total. That marks an 11.1% increase from its previous holding of 64,452 shares. The reported value of the stake reached $82,883,902 at the time of the filing.

Other Institutional Activity in Eli Lilly

Other institutional investors adjusted their positions in Eli Lilly around the same reporting date. Wilmington Savings Fund Society, FSB reduced its holdings by 2,600 shares, ending with 25,292 shares worth about $29,264,867. NTV Asset Management grew its holdings by 611 shares, ending with 31,222 shares worth about $36,126,352. Ascent Wealth Partners opened a new position, acquiring 9,135 shares worth about $10,570,131. Evergreen Capital Management grew its holdings by 1,878 shares, ending with 14,030 shares worth about $16,234,067. Symphony Financial grew its holdings by 1,205 shares, ending with 7,802 shares worth about $9,191,438.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly shares recently traded around $1,273.57 as of October 24, 2026, putting the stock right around its event-day close and below its 52-week high of $1,321.21. The stock trades well above its 50-day moving average of $1,185.32 and its 200-day moving average of $1,084.11.

Recent Earnings

Eli Lilly heads toward its next earnings update scheduled for October 29, 2026, backed by strong financial results in its trailing twelve month reports. The drug maker generated $79.67 billion in revenue over the period with earnings of $29.79 per share. Profitability remains high, shown by a net profit margin of 33.5% and a return on equity of 102.3%, alongside year-over-year revenue growth of 47.7%.

Dividend

Eli Lilly pays an annual dividend rate of $6.92 per share, which translates to a dividend yield of 0.53%. The company allocates 21.7% of its earnings toward dividend payments.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several stock sales prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, for a total value of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, valued at $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, for a total of $7,638,150.

Analysts Set New Price Targets

Wall Street firms maintain positive coverage on the healthcare company. JP Morgan maintained an Overweight rating and raised its price target to $1,500.00 on September 28, 2026. Morgan Stanley maintained an Overweight rating and lifted its target to $1,430.00 on October 7, 2026. Cantor Fitzgerald maintained an Overweight rating and raised its target to $1,440.00 on October 8, 2026. RBC Capital reiterated an Outperform rating with a $1,500.00 target on October 12, 2026. Leerink Partners maintained an Outperform rating and lifted its target to $1,316.00 on October 21, 2026. Overall, analysts give the stock a consensus buy rating with 30 analyst opinions tracked.

About Eli Lilly and Company

Eli Lilly and Company is a major healthcare business headquartered in Indianapolis, Indiana. The company researches, develops, and sells pharmaceutical products around the world, focusing on treatments in areas such as diabetes, oncology, and immunology. Institutional interest remains strong as the company brings new drug therapies to global markets.

Bottom Line

Investors will look to Eli Lilly's upcoming earnings report on October 29, 2026, for further updates on revenue and profit growth. Institutional filings like this one show how professional managers position their portfolios ahead of corporate updates.